Company ASLAN Pharmaceuticals Limited Taipei Exchange
Equities
6497
KYG054241099
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cancer Novel Drugs
100.0
%
| 0 | nan % | 12 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
100.0
%
| - | - | 12 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Carl Firth
FOU | Founder | 51 | 31/12/09 |
Kiran Asarpota
DFI | Director of Finance/CFO | 45 | 31/10/10 |
Chief Tech/Sci/R&D Officer | - | 14/03/22 | |
Stephen Doyle
PRN | Corporate Officer/Principal | 50 | 31/01/18 |
Ben Goodger
LAW | General Counsel | 61 | 31/10/16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hoffman
BRD | Director/Board Member | 58 | 29/10/18 |
Andrew Howden
CHM | Chairman | 64 | 31/03/16 |
Carl Firth
FOU | Founder | 51 | 31/12/09 |
Kathleen Metters
BRD | Director/Board Member | 66 | 17/03/21 |
Neil Graham
BRD | Director/Board Member | 65 | 17/02/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 337,297,360 | 333,924,386 ( 99.00 %) | 0 | 99.00 % |
Company contact information
Aslan Pharmaceuticals Ltd.
3 Temasek Avenue 18 Level Centennial Tower
039190, Singapore
+
http://www.aslanpharma.comSector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+10.44% | 106B | |
+0.82% | 104B | |
+6.72% | 23.25B | |
-13.89% | 22.5B | |
-6.64% | 18.7B | |
-37.26% | 17.95B | |
-10.98% | 16.99B | |
+8.67% | 14.26B | |
+41.08% | 12.76B |